1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This review underscores the profound and expanding therapeutic potential of GLP-1 receptor agonists, solidifying their role as cornerstone treatments for type 2 diabetes and obesity. The confirmed cardiovascular and r…
This scoping review is crucial for informing clinical guidelines and best practices for orthopedic surgeons, anesthesiologists, and perioperative care teams. Understanding the current evidence base regarding GLP-1 RA …
This review provides a strong theoretical and preliminary clinical basis for exploring GLP-1 RAs as novel adjuncts to cancer immunotherapy. The observed immunomodulatory effects and potential for enhanced efficacy, co…
This study highlights the critical importance of considering sex as a biological variable in metabolic research and drug development. The enhanced FGF21 response and profound metabolic improvements observed specifical…
This FDA approval of higher-dose semaglutide marks a significant advancement in the pharmacological treatment of obesity, offering a highly effective option for chronic weight management. The substantial and sustained…
This study's design was significant because it aimed to provide a head-to-head comparison of two distinct and highly effective drug classes—a GLP-1 receptor agonist and an SGLT2 inhibitor—in a critical patient populat…
This research holds significant promise for public health, as it targets a critical window for intervention to prevent Type 2 Diabetes (T2DM) in a high-risk group. Successful outcomes could establish semaglutide as a …
Understanding the precise gastric emptying kinetics in both healthy individuals and GLP-1 agonist users is critically important for optimizing treatment strategies and patient safety. The findings could lead to update…
This trial is crucial because it directly addresses a significant unmet need in treating HFpEF, especially in the context of obesity. If successful, it could establish Semaglutide as a novel therapeutic strategy for i…
If BGM0504 demonstrates comparable or superior efficacy and safety to Tirzepatide, it could represent a significant advancement in the treatment landscape for obesity. A new therapeutic option would provide clinicians…
The termination of this Phase 2 study means a potential avenue for enhanced obesity treatment in older adults remains unexplored. While tirzepatide is highly effective, combination therapies are often sought to improv…
This Randomized Control Trial is highly significant as it explores a novel strategy to enhance the effectiveness of bariatric surgery, potentially offering a more robust solution for severe obesity. If successful, com…
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
This study is significant because it addresses the complex interplay between inflammatory bowel disease and metabolic health, a common but often unaddressed clinical challenge. The key implication is that a combined t…
This compelling case report highlights the transformative potential of Semaglutide as a crucial therapeutic tool for obese patients awaiting lung transplantation. By facilitating rapid and significant weight loss, Sem…
This case report is significant because it raises awareness of a potentially novel adverse event associated with tirzepatide, a widely used and highly effective medication. If a causal link were established, it would …
The commentary underscores the transformative potential of Semaglutide in addressing the multifaceted challenges of obesity and its associated comorbidities. Its demonstrated efficacy across multiple physiological sys…
This comprehensive meta-analysis provides compelling and robust evidence that GLP-1 and dual GIP/GLP-1 receptor agonists offer substantial and multifaceted benefits for obese patients with HFpEF, extending significant…
This research highlights the superior patient experience and satisfaction associated with switching to Tirzepatide over escalating Dulaglutide in Type 2 Diabetes management. These findings provide crucial real-world e…
This critical appraisal underscores a crucial safety consideration for tirzepatide, a widely used and highly effective medication for type 2 diabetes and obesity. The identified increased risk of biliary diseases nece…
This review provides crucial evidence to guide clinical decision-making and optimize the allocation of these highly effective therapies, especially in healthcare systems facing resource constraints. By identifying spe…
This study provides crucial insights into the financial sustainability of covering highly effective, yet expensive, medications like Semaglutide within Medicare. The findings underscore the the significant potential f…
This study provides compelling evidence that semaglutide offers a dual therapeutic benefit, simultaneously addressing liver fibrosis and cardiovascular risk in patients already at high risk for advanced liver disease.…
The termination of a Phase 2 trial for a novel compound like PF-07081532 is a significant event in drug development, often signaling issues with safety, efficacy, or strategic priorities. While the specific reasons fo…
This study provides compelling evidence that semaglutide 2.4 mg once-weekly is a highly effective and generally well-tolerated treatment for chronic weight management in adults with overweight or obesity. The magnitud…
While this specific study was withdrawn, the broader context of its aims remains highly relevant for Type 2 Diabetes management. Understanding real-world effectiveness and adherence is crucial for optimizing patient o…
This planned randomized clinical trial holds significant promise for addressing the growing public health challenge of cognitive decline in older adults with Type 2 diabetes. If successful, the findings could provide …
This study is significant because it directly addresses the need for ethnically diverse clinical data in obesity treatment. The findings will provide crucial insights into how Semaglutide 2.4mg performs in the Latino …
Understanding the interplay between GLP-1 receptor agonists like semaglutide and the ghrelin system is crucial for optimizing obesity treatments. If blocking the ghrelin receptor with LEAP2 proves beneficial, it could…
This research holds significant promise as it investigates a novel approach to treating psoriasis by targeting its metabolic underpinnings, rather than just skin symptoms. If successful, it could demonstrate that Sema…
This study is crucial for enhancing patient safety during surgical procedures for individuals on GLP-1 agonists. The findings will help identify specific patient populations who require additional risk stratification,…
The withdrawal of this study means a valuable opportunity to directly compare these important first-line diabetes treatments has been lost. Had it proceeded, the trial could have provided critical head-to-head data, p…
This research is profoundly important as Type 2 Diabetes (T2D) significantly elevates the risk of severe cerebrovascular events like stroke, and understanding semaglutide's direct impact on brain health is critical. I…
The anticipated findings from this study underscore the potential of semaglutide 2.4 mg as a highly effective treatment option for individuals managing both Type 2 Diabetes and obesity. By addressing both conditions s…
The high and increasing prevalence of adolescent severe obesity underscores the urgent need for more effective and sustainable treatment strategies. If successful, this trial could demonstrate that combining semagluti…
This study is profoundly crucial for validating the cardiovascular benefits of semaglutide 2.4 mg in a real-world setting, offering invaluable data that complements and extends findings from highly controlled clinical…
Understanding the optimal pre-procedural management for patients on GLP-1RAs like semaglutide is critical for patient safety and procedural efficacy during endoscopy. If a one-week discontinuation significantly reduce…
This study holds significant implications for the obesity treatment landscape. A successful outcome, demonstrating comparable or superior efficacy and safety, could introduce a new, potentially more accessible or cost…
This trial is critically important because it directly compares the anti-atherosclerotic potential of newer, cardio-protective antidiabetic drugs against a long-standing standard in a high-risk population. If semaglut…